Literature DB >> 11120494

Cost-effectiveness of urodynamic testing before surgery for women with pelvic organ prolapse and stress urinary incontinence.

A M Weber1, M D Walters.   

Abstract

OBJECTIVE: This study was undertaken to compare cost-effectiveness between 2 preoperative testing strategies for women with pelvic organ prolapse and stress urinary incontinence symptoms. STUDY
DESIGN: We developed decision-analytic models that evaluated the cost-effectiveness of basic office evaluation before surgery in women with prolapse and stress urinary incontinence symptoms and contrasted it with that of urodynamic testing. Costs were obtained from the Federal Register; effectiveness of treatment for urinary incontinence was based on the published literature.
RESULTS: The strategies of basic office evaluation and urodynamic testing had the same cure rate of urinary incontinence (96%) after initial and secondary treatment. Under baseline assumptions incremental cost-effectiveness (cost for single extra cure of urinary incontinence) of urodynamic testing was $328,601. According to sensitivity analyses, basic office evaluation was more cost-effective than urodynamic testing when the prevalence of pure detrusor instability was <8% or when the cost of urodynamic testing was >$103.
CONCLUSION: Urodynamic testing before surgery in women with prolapse and stress urinary incontinence symptoms is not cost-effective relative to basic office evaluation.

Entities:  

Mesh:

Year:  2000        PMID: 11120494     DOI: 10.1067/mob.2000.111251

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  The impact of multichannel urodynamics upon treatment recommendations for female urinary incontinence.

Authors:  Renée M Ward; Brittany Star Hampton; Jeffrey D Blume; Vivian W Sung; Charles R Rardin; Deborah L Myers
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-04-19

Review 2.  Regenerative medicine based applications to combat stress urinary incontinence.

Authors:  Hatim Thaker; Arun K Sharma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

3.  Primary stress urinary incontinence: what to do and why.

Authors:  Jhansi Reddy; Marie Fidela R Paraiso
Journal:  Rev Obstet Gynecol       Date:  2010

4.  Incontinence and detrusor dysfunction associated with pelvic organ prolapse: clinical value of preoperative urodynamic evaluation.

Authors:  Isao Araki; Yaburu Haneda; Yuki Mikami; Masayuki Takeda
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-07-14

5.  Role of urodynamics before prolapse surgery.

Authors:  Maurizio Serati; Ilias Giarenis; Michele Meschia; Linda Cardozo
Journal:  Int Urogynecol J       Date:  2014-10-15       Impact factor: 2.894

6.  Promising impact of platelet rich plasma and carbon dioxide laser for stress urinary incontinence.

Authors:  Fariba Behnia-Willison; Tran T T Nguyen; Aidan J Norbury; Behrang Mohamadi; Stefano Salvatore; Alan Lam
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-10-22

7.  The evidence for urodynamic investigation of patients with symptoms of urinary incontinence.

Authors:  Peter F Rosier
Journal:  F1000Prime Rep       Date:  2013-03-04

8.  Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice.

Authors:  G Ghoniem; E Stanford; K Kenton; C Achtari; R Goldberg; T Mascarenhas; M Parekh; K Tamussino; S Tosson; G Lose; E Petri
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-11-17

9.  Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study.

Authors:  Ilias Goranitis; Pelham Barton; Lee J Middleton; Jonathan J Deeks; Jane P Daniels; Pallavi Latthe; Arri Coomarasamy; Suneetha Rachaneni; Shanteela McCooty; Tina S Verghese; Tracy E Roberts
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.